C反应蛋白与白蛋白比值在胰腺癌患者中的预后及临床病理意义：一项荟萃分析
Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis.
作者信息
Xie Qinfen, Wang Lidong, Zheng Shusen
机构信息
Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang, China.
出版信息
Dose Response. 2020 Jun 29;18(2):1559325820931290. doi: 10.1177/1559325820931290. eCollection 2020 Apr-Jun.
BACKGROUND
This meta-analysis explored the correlation between the C-reactive protein to albumin ratio (CAR) and survival outcomes and clinicopathological characteristics in patients with pancreatic cancer.
METHODS
PubMed, Embase, Web of Science, and Cochrane Library databases were comprehensively searched through October 17, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the association between CAR and overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in pancreatic cancer.
RESULTS
The meta-analysis included 11 studies comprising 2271 patients. The pooled results showed that a high CAR was predictive of worse OS (HR = 1.84, 95% CI = 1.65-2.06, < .001), PFS (HR = 1.53, 95% CI = 1.27-1.85, < .001), and DFS (HR = 1.77, 95% CI = 1.30-2.41, < .001). An elevated CAR was also associated with male sex (OR = 1.38, 95% CI = 1.10-1.74, = .006).
CONCLUSION
Elevated pretreatment CAR effectively predicts inferior survival outcomes in patients with pancreatic cancer and may be a powerful prognostic indicator for these patients.
背景
本荟萃分析探讨了胰腺癌患者C反应蛋白与白蛋白比值（CAR）与生存结局及临床病理特征之间的相关性。
方法
全面检索了截至2019年10月17日的PubMed、Embase、Web of Science和Cochrane图书馆数据库。采用合并风险比（HR）和95%置信区间（CI）评估CAR与胰腺癌患者总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）之间的关联。
结果
该荟萃分析纳入了11项研究，共2271例患者。合并结果显示，高CAR预示着更差的OS（HR = 1.84，95%CI = 1.65 - 2.06，P <.001）、PFS（HR = 1.53，95%CI = 1.27 - 1.85，P <.001）和DFS（HR = 1.77，95%CI = 1.30 - 2.41，P <.001）。CAR升高还与男性性别相关（OR = 1.38，95%CI = 1.10 - 1.74，P =.006）。
结论
治疗前CAR升高可有效预测胰腺癌患者较差的生存结局，可能是这些患者强有力的预后指标。
Zotero 插件